Recent Updates
Recently added Catalysts
ALDX Positive Sentiment

Aldeyra Therapeutics to Host Regulatory Update Webcast

Monday, September 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Aldeyra Therapeutics will host a regulatory update webcast on September 29, 2026, focusing on reproxalap, its investigational drug for dry eye disease. This event aims to provide insights into the drug's development and regulatory status. The webcast will include a live audio presentation and slides for attendees.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aldeyra is actively engaging with stakeholders through a webcast.
  • The focus on reproxalap highlights the company's commitment to innovation.
  • The investigational drug targets a significant health issue, dry eye disease.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+6%
120-day peak, hindsight
Typical move
15.2%
average across 13 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
ADX-629
Phase 2 · Covid19

Full Press Release Details

CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease. A live audio webcast and slide presentation will be accessible from

Frequently Asked Questions

When is Aldeyra's regulatory update webcast?

The webcast is scheduled for September 29, 2026, at 8:00 a.m. ET.

What will the webcast focus on?

The update will focus on reproxalap, an investigational drug for dry eye disease.

How can I access the webcast?

A live audio webcast and slide presentation will be accessible online.

What is reproxalap designed to treat?

Reproxalap is designed to treat dry eye disease.

ShareAdd on Google
Tags: ALDX Aldeyra Therapeutics reproxalap dry eye disease regulatory update biotechnology
Last updated: Sep 28, 2026

Biotech snapshot

Cash runway
$45M liquidity · $2M/mo burn
~28 mo
Minimal dilution risk
Lead asset
ADX-629Phase 2
Covid19 →

Catalyst track record

+6%
best trade around ALDX's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for ALDX.

See every catalyst's timing & PoA →